- Home
- CELC vs HYLN Comparison
CELC vs HYLN Comparison
Compare CELC & HYLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- HYLN
- Stock Information
- Founded
- CELC 2011
- HYLN 2018
- Country
- CELC United States
- HYLN United States
- Employees
- CELC N/A
- HYLN N/A
- Industry
- CELC Medical Specialities
- HYLN Construction/Ag Equipment/Trucks
- Sector
- CELC Health Care
- HYLN Consumer Discretionary
- Exchange
- CELC Nasdaq
- HYLN Nasdaq
- Market Cap
- CELC 327.3M
- HYLN 279.7M
- IPO Year
- CELC 2017
- HYLN N/A
- Fundamental
- Price
- CELC $10.15
- HYLN $1.64
- Analyst Decision
- CELC Strong Buy
- HYLN Hold
- Analyst Count
- CELC 6
- HYLN 1
- Target Price
- CELC $30.17
- HYLN $2.00
- AVG Volume (30 Days)
- CELC 190.9K
- HYLN 659.3K
- Earning Date
- CELC 05-14-2025
- HYLN 05-13-2025
- Dividend Yield
- CELC N/A
- HYLN N/A
- EPS Growth
- CELC N/A
- HYLN N/A
- EPS
- CELC N/A
- HYLN N/A
- Revenue
- CELC N/A
- HYLN $1,509,000.00
- Revenue This Year
- CELC N/A
- HYLN $741.55
- Revenue Next Year
- CELC N/A
- HYLN $185.14
- P/E Ratio
- CELC N/A
- HYLN N/A
- Revenue Growth
- CELC N/A
- HYLN 124.55
- 52 Week Low
- CELC $7.58
- HYLN $1.17
- 52 Week High
- CELC $19.77
- HYLN $4.10
- Technical
- Relative Strength Index (RSI)
- CELC 46.58
- HYLN 56.93
- Support Level
- CELC $9.64
- HYLN $1.53
- Resistance Level
- CELC $10.80
- HYLN $1.69
- Average True Range (ATR)
- CELC 0.66
- HYLN 0.08
- MACD
- CELC -0.06
- HYLN 0.02
- Stochastic Oscillator
- CELC 25.25
- HYLN 79.25
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.